GILD · News · 20261105N

Livdelzi Demand Growth

GILEAD SCIENCES, INC. · 2026-11-05 · Importance 34 · Surprise 42

Phase 3 IDEAL results support expanding Livdelzi (seladelpar) use among people with primary biliary cholangitis (PBC), including patients with lower alkaline phosphatase (ALP) elevation. At week 52, 75.4% of patients in that group achieved the study’s composite ALP normalization endpoint. The results could support broader use beyond Livdelzi’s current scope, and Gilead plans to engage global regulatory authorities based on the findings. Data are to be presented at the American Association for the Study of Liver Diseases’ annual meeting.

Key facts

• Gilead is seeking to expand the patient population for Livdelzi (seladelpar) for primary biliary cholangitis following positive Phase III IDEAL results. source
• Gilead announced detailed Phase 3 IDEAL study results for Livdelzi (seladelpar) in people with primary biliary cholangitis (PBC). source
• In the Phase 3 IDEAL study, 75.4% of patients with lower alkaline phosphatase elevation achieved composite ALP normalization at week 52. source